Gene therapy for lysosomal storage disorders

Expert Opinion on Biological Therapy

Volumn 1, Issue 5, 2001, Pages 857-867

  Novelli, Enrico M ^a   Barranger, John A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Animal models; BMT; Enzyme replacement; Gene transfer; Lysosomal storage disorders; Therapy

Indexed keywords

ANIMAL; DNA VECTOR; GENE THERAPY; GENE TRANSFER; GENETICS; HUMAN; INSTRUMENTATION; LYSOSOME STORAGE DISEASE; METHODOLOGY; REVIEW;

ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMAN; LYSOSOMAL STORAGE DISEASES;

EID: 0035459890     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.5.857     Document Type: Article

References (104)

1. BARTON NW, BRADY RO, DAMBROSIA JM etal: Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease [sec comments]. N. EngLj. Med. (1991) 324:1464-1470.
2. PASTURES GM, SIBILLE AR GRABOWSKI GA: Enzyme therapy in Gaucher disease Type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. AW (1993) 82:408-416.
3. BRADY RO, SCHIFFMANN R: Clinical features of and recent advances in therapy for Fabry disease. JAMA (2000) 284:2771-2775.
4. SCHIFFMANN R, MURRAY GJ, TRECO D et al.: Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Prof. NatL Acad. Sei. USA (2000) 97:365-370. First report of successful ERT for Fabry disease.
5. ENG CBANIKAZEMI M.GORDON R et ai: A Phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. (2001) 68:711-722.
6. CHEN Y: Pompe update and trial design. In: Interventional genetics for lysosomal storage disorders: from diagnostics to therapeutics. Philadelphia, USA (2000).
7. VAN DEN HOUT H, REUSER A, VULTO Pi. et ai: Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet (2000) 356:397-398. Clinical trial of successful ERT for Pompe disease.
8. KAKKIS ED, MUENZER J, TILLER GE et al: Enzyme-replacement therapy in mucopolysaccharidosis I. N. EngL J. Med. (2001) 344:182-188. First report of successful ERT for human MPSI.
9. DEAN MF, STEVENS RUMUIR H et ab. Enzyme replacement therapy by fibroblast transplantation: long-term biochemical study in three cases of Hunter's syndrome.J. Clin. Invest. (1979) 63:138-145.
10. KRiVANG. TIMARUGODAV et al: Bone marrow transplantation in nonmalignant disorders. Bone Marrow Transplant. (1998) 22(Suppl. 4):S80-83.
11. BOU-GHARIOSG, ABRAHAM D, OLSEN I: Lysosomal storage diseases: mechanisms of enzyme replacement therapy. Histochcm.]. (1993) 25:593-605.
12. BIRKENMEIER EH, DAVISSON MT, BEAMER WG etal: Murine mucopolysaccharidosis Type VII. Characterization of a mouse with betaglucuronidase deficiency. J. Clin. Invest. (1989) 83:1258-1256.
13. SLYWS, VOGLER C,GRUBBJHr/zZ: Active site mutant transgene confers tolerance to human beta - glucuronidase without affecting the phenotype of MPS VII mice. Proc. NatlAcad. Sei. USA (2001) 98:2205-2210.
14. DUCHEN L, EICHER E, JACOBS], SCARAVILLIF TEDIRA F: A globoid type of leukodystrophy in the mouse the mutant twitcher. In: Neurological Mutations Affecting Myelination. N Bauman (Ed.), Elsevier, Amsterdam, The Netherlands (1980):107.
15. OHSHIMA T, MURRAY GJ, SWAIM WD et al: Alpha-Galactosidase A deficient mice: a model of Fabry disease. froc. NatL Acad. Sei. USA (1997) 94:2540-2544.
16. RABENN, NAGARAJUK, LEEErtaJ.: Targeted disruption of the acid alphaglucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease Type II. J. BioL Chem. (1998) 273:19086-19092.
17. TYBULEWICZVL.TREMBLAYML, LAMARCA ME ctaL: Animal model of Gauchers disease from targeted disruption of the mouse glucocerebrosidase gene. Nature (1992) 357:407-410.
18. HESS B, SAFTIG P, HARTMANN D et al.: Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. Proc. NatL Acad. Sei. USA (1996) 93:14821-14826.
19. SANGO K, YAMANAKA S, HOFFMANN A etal.: Mouse models of Tay-Sachs and Sandhoff discases differ in neurologic phenotype and ganglioside metabolism. Nature Genet. (1995) 11:170-176.
20. BARRANGERJ.GINNSE: Glucosylceramide lipidoses: Gaucher disease. In: The matabolic basis of inherited disease. AB CR Scriver, WS Sly, D Vallc (Eds.), McGraw-Hill, New York (NY), (1989):1677-1698.
21. RAPPEPORT JM GINNS EI: Bone-marrow transplantation in severe Gaucher's disease. W. EnglJ. Med. (1984) 311:84-88.
22. HOOGERBRUGGE PM, BROUWER OF, BORDIGONIP et al.: Allogeneicbone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation [see comments). Lancet (1995) 345:1398-1402.
23. HOOGERBRUGGE PM, VALERIO D: Bone marrow transplantation and gene therapy for lysosomal storage diseases. Bone Marrow Transfiant. (1998) 21:534-36.
24. BARTON NW, FURBISH FS, MURRAY GJ, GARFIELD M, BRADY RO: Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc, NatL Acad. Sei. USA (1990) 87:1913-1916.
25. GRABOWSKIGA, LESLIE N WENSTRUP R: Enzyme therapy for Gaucher disease: the first 5 years. BlaodRcv. (1998) 12:115-133.
26. CORRELL PH, COLILLA S, DAVE HP, KARLSSON S: High levels of human glucocerebrosidase activity in macrophages of long- term reconstituted mice after retroviral infection of hematopoietic stem cells. SW(I992) 80:331-336.
27. OHASHIT.BOGGSS.ROBBINSP et al.: Efficient transfer and sustained high expression of the human glucocerebrosidase gene in mice and trieir functional macrophages following transplantation of bone marrow transduced by a retroviral vector. Proc. NatL Acad. Sei. USA (1992) 89:11332-11336.
28. BAHNSON AB, NIMGAONKAR M, FEI YetaL: Transduction of CD34+ enriched cord blood and Gaucher bone marrow cells by a retroviral vector carrying the glucocerebrosidase gene. Genf Ther. (1994) 1:176-184.
29. NIMGAONKAR MT, BAHNSON AB, BOGGS SS, BALL ED, BARRANGER JA: Transduction of mobilized peripheral blood CD34+ cells with the glucocerebrosidase cDNA. Gene Ther. (1994) 1:201-207.
30. MANNION-HENDERSON J. KEMPA, MOHNEYT ctaL: Efficient retroviral mediated transfer of the glucocerebrosidase gene in CD34+ enriched umbilical cord blood human hematopoietic progenitors. Exp. HematoL (1995) 23:1628-1632.
31. NIMGAONKAR M, BAHNSON A, KEMP A et ai: Long-term expression of the glucocerebrosidasc gene in mouse and human hcmatopoietic progenitors. Leukemia (1995) 9(SuppI. l):S38-42.
32. SCHUENING F, LONGO WL, ATKINSON ME etal.: Rctrovirus-mediated transfer of the cDNA for human glucocerebrosidase into peripheral blood repopulating cells of patients with Gauchers disease. Num. Gene Thfr. (1997) 8:2143-2160.
33. DUNBARCE. KOHN DB, SCHIFFMANN R et ai: Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum. Gene Ther. (1998) 9:2629-2640.
34. NOVELLIEM. SWANEYSWRKOPPD ctaL:A Phase I trial of retroviral-mediated gene therapy of Gaucher Disease. Blood (2000):96S. Evidence of correction of phenotype in a clinical trial of gene therapy for Gaucher disease.
35. PARKMANR, WEINBERG K, CROOKS G et ai: Gene therapy for adenosine deaminase deficiency. Ann. Rev. Med. (2000) 51:33-47.
36. Using Smart Source Parsing. 36. CASE SS, PRICE MA, JORDAN CT etal: Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc. NatLAcad. Sei. USA (1999) 96:2988-2993.
37. NALDINIL, BLOMERU, GALLAYPrt aL: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector [see comments]. Science (1996) 272:263-267.
38. AMADO RG, CHEN IS: Lentiviral vectors - the promise of gene therapy within reach? Science (1999) 285:674-676.
39. MIYOSHI H, SMITH KA, MOSIER DE, VERMA IM TORBETT BE: Transduction of human CD34+ cells that mediate longterm engraftment of NOD/SCID mice by HIV vectors. Science (1999) 283:683-686. Use of lentiviral vectors to transduce human HSC.
40. BLOMERU, NALDINIL, KAFRITrt/2J.: Highly efficient and sustained gene transfer in adult neurons with a Icntivirus vector. J. Viral. (1997)71:6641-6649.
41. DAOMA, TAYLORN, NOLTAJA: Reduction in levels of the cyclin-dependent kinase inhibitor p27(kip-l) coupled with transforming growth factor beta neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells. Proc. NatL Acad. Sei. USA (1998) 95:13006-13011.
42. SWANEY WP, SORGI FL, BAHNSON AB, BARRANGER JA: The efTect of cationic liposome pretreatment and centrifugation on retrovirus-mediated gene transfer Gene Ther. (1997) 4:1379-1386.
43. LIU C, BAHNSON AB, DUNIGAN JT, WATKINS SC, BARRANGERJA: Long-term expression and secretion of human glucocerebrosidase by primary murine and human myoblasts and differentiated myotubes [see comments].J. Mol. Med. (1998)76:773-781.
44. LIU C, DUNIGAN JT, WATKINS SC, BAHNSON AB, BARRANGERJA: Long-term expression, systemic deliver}1, and macrophage uptake of recombinant human glucocerebrosidase in mice transplanted with genetically modified primär)' myoblasts. Hum. Gene Ther. (1998) 9:2375-2384.
45. KAYE EM, KOLODNY EH, LOGICIAN EL, ULLMAN MD: Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann. NeuroL (1988) 23:505-509.
46. TAKENAKAT. HENDRICKSONCS, TWOREK DM et aL: Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease. Exp. HematoL (1999) 27:1149-1159.
47. TAKIYAMAN, DUNIGAN JT.VALLOR MJ etaL: Retrovirus-mediated transfer of human alpha-galactosidasc A gene to human CD34+ hematopoietic progenitor cells. Hum. Gene Ther. (1999) 10:28812889.
48. TAKENAKAT, MURRAY GJ.QIN G et aL: Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells. Proc. NatL Acad. Sei. USA (2000) 97:7515-7520. Promising gene therapy approach for Fabry disease.
49. JUNGSCHANIP. LIMAYE Art: Adeno-associated viral vector-mediated gene transfer results in long- term enzymatic and functional correction in multiple organs of Fabry mice. Proc. NatL Acad. Sei. USA (2001) 98:2676-2681. Report on the efficacy of AAV in an animal model.
50. PHILLIPS MI: Antisensc inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension (1997) 29:177-187.
51. NAKAIH.STORMTA.KAYMA: Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo.]. VtroL (2000) 74:9451-9463.
52. HIRSCHHORN R: Glycogen storage disease Type II: Acid alfa-glucosidase (acid maltase) deficiency. In: The metabolic and molecular bases of inherited disease. C Scriver, A Beaudet, W Sly, D Valle (Eds.) McGraw-Hill (1995):2443-2464.
53. ZARETSKY JZ, CANDOTTIF, BOERKOEL C eta!.: Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion. Hum. Gene Ther. (1997) 8:1555-1563.
54. NICOLINO MP, PUECH JP, KREMER EJ et ai: Adenovirus-mediated transfer of the acid alpha-glucosidase gene into fibroblasts, myoblasts and myotubes from patients with glycogen storage disease Type II leads to high level expression of enzyme and corrects glycogcn accumulation. Hum. Mol Genet. (1998) 7:1695-1702.
55. TSUJINO S, KINOSHITA N, TASHIRO T et ai: Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of Japanese quail with acid maltase deficiency. Hum. Gene Ther. (1998) 9:1609-1616.
56. AMALFITANOA. MCVIE-WYLIEA J, HU H étal: Systemic correction of the muscle disorder glycogen storage disease Type II after hepatic targeting of a modified adenovirus vector encoding human acidalpha-glucosidase. Proc. NatL Acad. Set. USA (1999) 96:8861-8866. Report of an adenoviral-mediatcd approach for Pompe disease that shows systemic correction.
57. YEAGERA:Hematopoieticcell transplantation for storage diseases. In: Hematopoietic cell transplantation. T Donnall, K Blume, F SJ (Eds.) Oxford, Maiden (MA), (1999):! 182-1194.
58. LEARISH R, OHASHI T, ROBBINS PA et al: Retroviral gene transfer and sustained expression of human arylsulfatase A. Gène Ther. (1996) 3:343-349.
59. MATZNER U, HARZER K, LEARISH RD, BARRANGER JA, G1ESELMANN V: Long-term expression and transfer of arylsulfatase A into brain of arylsulfatase A-deficient mice transplanted with bone marrow expressing the arylsulfatase A cDNA from a retroviral vector. Gene Thcr. (2000) 7:1250-1257.
60. WOLFEJH, SANDS MS, BARKERJE et aL: Reversal of pathology in murine mucopolysaccharidosis Type VII by somatic cell gene transfer. Nature (1992) 360:749-753. Partial correction of MPS VII by transplanted retrovirally marked stem cells.
61. MARECHAL V, NAFFAKH N, DANOS O, HEARD JM: Disappearance of lysosomal storage in spleen and liver of mucopolysaccharidosis VII mice after transplantation of genetically modified bone marrow cells. AW (1993) 82:1358-1365.
62. OHASHIT, YOKOO T, IIZUKA S et al: Reduction of lysosomal storage in murine mucopolysaccharidosis Type VII by transplantation of normal and genetically modified macrophages. B!aod (2000) 95:3631-3633.
63. DESHMANESUVALYI-NAGYT, BLOCKT étal: An HSV-1 containing the rat beta-glucuronidase cDNA inserted within the LAT gene is less efficient than the parental strain at establishing a transcriptionally active state during latency in neurons. Gene Ther. (1995) 2:209-217.
64. BOSCH A, PERRET E, DESMARIS N, HEARD JM: Long-term and significant correction of brain lesions in adult mucopolysaccharidosis Type VII mice using recombinant AAV vectors. Mol Ther. (2000) 1:63-70.
65. BOSCH A, PERRET E, DESMARIS N, TRONO D, HEARD JM: Reversal of pathology in the entire brain of mucopolysaccharidosis Type VII mice after lentivirus-mediated gene transfer. Hum. Gene Ther. (2000) 11:1139-1150.
66. CONSIGLIOA,QUATTRINIA, MARTINO S étal: In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nature Med. (2001) 7:310-316. Interesting report on in vivo lentiviral-mediatcd gene transfer.
67. TAYLOR RM, WOLFE JH: Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of rctroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. Nature Med. (1997) 3:771-774.
68. GROVES AKBARNETTSC, FRANKLIN RJ etaL: Repair of demyelinated lesions by transplantation of purified O-2A progenitor cells. Nature (1993) 362:453-455. An important report on neurotransplantation.
69. LACHAPELLEF, DUHAMEL-CLERIN E, GANSMULLER A et ai: Transplanted transgenically marked oligodendrocytcs survive, migrate and myelinate in the normal mouse brain as they do in the shiverer mouse brain. Eur. J. Neurosci. (1994)6:814-824.
70. LOUIS JC, MAGALE.MUIRD, MANTHORPE M, VARON S: CG-4, a new bipotential glial cell line from rat brain, is capable of differentiating in vitro into either mature oligodendrocytes or type-2 astrocytes.J. Nturosci. Res. (1992) 31:193-204.
71. SNYDEREY.DEITCHERDUWALSHC et aL: Multipotent neural cell lines can engraft and participate in development of mouse cerebellum. O//Ü992) 68:33-51. The first report of cell line neurotransplantation.
72. TONTSCH U, ARCHER DR, DUBOISDALCQM, DUNCAN ID: Transplantation of an oligodendrocyte cell line leading to extensive myelination. Proc. NatlAcad. Sa. USA (1994) 91:11616-11620.
73. SNYDEREY.TAYLOR RM, WOLFE JH: Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature (1995) 374:367-370.
74. LACORAZZAHD.FLAXJD.SNYDER EY, JENDOUBI M: Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nature Med. (1996) 2:424-429. Report of successful transplantation of gene-corrected CNS progenitors into the brain of fetal and newborn mice.
75. ROSS CJ. BASTEDOL, MAIER SA, SANDS MS, CHANG PL: Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated rccombinant cells. Hum. Gene Ther. (2000) 11:2117-2127.
76. ROSS CJ, RALPH M, CHANG PL: Somatic gene therapy for a neurodegenerativc disease using microencapsulated recombinant cells. Exp. NeuroL (2000) 166:276-286.
77. KOSUGA M, SASAKI K, TANABE A et al: Engraftment of genetically engineered amniotic epithelial cells corrects lysosomal storage in multiple areas of the brain in mucopolysaccharidosis type vii mice. Mol. Thcr. (2001) 3:139-148.
78. DEANS RJ, MOSELEY AB: Mesenchymal stem cells: biology and potential clinical uses. Exp. HematoL (2000) 28:875-884.
79. AZIZI SA, STOKES D, AUGELLI BJ, DIGIROLAMO C, PROCKOP DJ: Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats - similarities to astrocytc grafts. Proc. NatL AcatL Sei. USA (1998) 95:3908-3913.
80. KOPEN GC, PROCKOP DJ, PHINNEY DG: Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc. NatlAcad. Set. USA (1999) 96:10711-10716. An intriguing report on the multi-lineage differentiation potential of MSC.
81. PITTENGER MF, MACKAY AM, BECK SC eta!.: Multilineage potential of adult human mesenchymal stem cells. Science (1999) 284:143-147.
82. MARX JC, ALLAY JA, PERSONS DA et aL: High-efficiency transduction and long-term gene expression with a murine stem cell retroviral vector encoding the green fluorescent protein in human marrow stromal cells. Hum. Gent Ther. (1999) 10:1163-1173.
83. SCHWARZ EJ, ALEXANDER GM, PROCKOP DJ, AZIZI SA: Muldpotential marrow stromal cells transduced to produce L-DOPA: engrartment in a rat model of Parkinsons disease. Hum. Gene Ther, (1999) 10:2539-2549.
84. DALYTM, VOGLER C, LEVY B, HASKINS ME, SANDS MS: Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc. NatL Acad. Sei. USA (1999) 96:2296-2300.
85. PODUSLOSE.TENNEKOONG, PRICE D, MILLER K, MCKHANN GM: Fetal metachromatic leukodystrophy: pathology, biochemistry and a study of in vitro enzyme replacement in CNS tissue. J. NeurofathoL Exp. NeuroL (1976) 35:622-632.
86. BAIER W, HARZER K: Sulfatidcs in prenatal metachromatic leukodystrophy. J. Neurochcm. (1983) 41:1766-1768.
87. ADACHIM,SCHNECKL,VOLKBW: Ultrastructural studies of eight cases of fetal Tay-Sachs disease. Lab. Invest. (1974) 30:102-112.
88. KAYE EM, ULLMANMD, WILSON ER, BARRANGER JA: Type 2 and Type 3 Gaucher disease: a morphological and biochemical study. Ann. Neural. (1986) 20:223-230.
89. SCHNEIDER EL, ELLIS WG, BRADY RO, MCCULLOCH JR, EPSTEIN CJ: Infantile (type II) Gaucher's disease: in utero diagnosis and fetal pathology. ]. Pediatr. (1972)81:1134-1139.
90. SIDRANSKYE.SHERERDM.GINNS El: Gaucher disease in the neonate: a distinct Gaucher phenotypc is analogous to a mouse model created by targeted disruption of the glucocerebrosidase gene. Pediatr. Res. (1992) 32:494-498.
91. KAYE EM: Therapeutic approaches to lysosomal storage diseases. Curr. Of in. Pediatr. (1995) 7:650-654.
92. IMAIZUMIM, GUSHIK, KUROBANEI etaL: Long-term effects of bone marrow transplantation for inborn errors of metabolism: a study of four patients with lysosomal storage diseases. ACTA Paediatr. Jpn. (1994) 36:30-36.
93. FLAKE AW, ZANJANI ED: In utero hematopoietic stem cell transplantation: ontogenic opportunities and biologic barriers. AW (1999) 94:2179-2191. An extensive review of in utero HSC transplantation.
94. LUTZKO C, OMORI F, ABRAMS-OGG AC et aL\ Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease. Hum. Gene Ther. (1999) 10:1521-1532.
95. ZANJANI ED, ANDERSONWF: Prospects for in utero human gene therapy. Science (1999) 285:2084-2088. An expert opinion on in utero gene therapy.
96. MISTRY PK: Treatment of Gaucher's disease with OGT 918. Lancet (2000) 356:676-677. Report of a clinical trial of substrate inhibition for Gaucher disease.
97. JEYAKUMARM. NORFLUSF. TIFFTCJ etaL: Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation. Blood(2001) 97:327-329.
98. HOLLON T: Researchers and regulators reflect on first gene therapy death. Nature Med. (2000) 6:6.
99. CAVAZZANA-CALVOM, HACEIN-BEY S, DE SAINT BASILE G étal: Gene therapy of human severe combined immunodeficiency (SCID)-Xl disease [see comments]. Science (2000) 288:669-672. Report of the first successful gene therapy clinical trial.
100. MALECH HL, MAPLES PB, WHITING-THEOBALD N étal: Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc. Natl Acad. Set. USA (1997) 94:12133-12138.
101. MALECH HL: Use of serum-free medium with fibronectin fragment enhanced transduction in a system of gas permeable plastic containers to achieve high levels of retrovirus transduction at clinical scale. Stem Cells (2000) 18:155-156. Using Smart Source Parsing.
102. KAY MA, MANNO CS, RAGNIMV et al: Evidence for gene transfer and expression of Factor DC in haemophilia B patients treated with an AAV vector [see comments]. Nature Genet. (2000) 24:257-261. Clinical trial of AAV-mediated gene therapy for haemophilia B show modest changes in clinical cndpoints.
103. ABONOUR R, WILLIAMS DA, EINHORN L étal: Efficient rctrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term populating hcmatopoietic stem cells [see comments]. Nature Med. (2000) 6:652-658. A promising gene therapy strategy for the treatment of malignancy.
104. FREED CR, GREENE PE, BREEZE RE et al: Transplantation of embryonic dopaminc neurons for severe Parkinson's disease. N. EngLJ. Med. (2001) 344:710-719.